Luis Querol1, Pamela L Clark, Mary A Bailey, Chris Cotsapas, Anne H Cross, David A Hafler, Steven H Kleinstein, Jae-Yun Lee, Gur Yaari, Simon N Willis, Kevin C O'Connor. 1. From the Department of Neurology (L.Q., P.L.C., M.A.B., C.C., D.A.H., J.-Y.L., K.C.O.), Human and Translational Immunology Program (D.A.H., K.C.O.), Department of Genetics (C.C.), Department of Pathology (S.H.K., G.Y.), and Department of Immunobiology (D.A.H.), Yale School of Medicine, New Haven, CT; Neuromuscular Diseases Unit (L.Q.), Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Spain; Medical and Population Genetics (C.C.), Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (A.H.C.), Washington University School of Medicine, St. Louis, MO; Interdepartmental Program in Computational Biology and Bioinformatics (S.H.K.), Yale University, New Haven, CT; and Department of Neurology (S.N.W.), Harvard Medical School and Brigham and Women's Hospital, Boston, MA. Simon N. Willis is currently affiliated with the Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Abstract
OBJECTIVE: To profile the reactivity of CSF-derived immunoglobulin from patients with multiple sclerosis (MS) against a large panel of antigens, to identify disease-specific reactivities. METHODS: CSF from subjects with MS with elevated immunoglobulin G and CSF from control subjects presenting with other inflammatory neurologic disease were screened against a protein array consisting of 9,393 proteins. Reactivity to a candidate protein identified using these arrays was confirmed with ELISA and immunocytochemistry. RESULTS: Autoantibodies against one protein on the array, recombination signal binding protein for immunoglobulin kappa J region (RBPJ), discriminated between patients with MS and controls (p = 0.0052). Using a large validation cohort, we found a higher prevalence of autoantibodies against RBPJ in the CSF of patients with MS (12.5%) compared with the CSF of patients with other neurologic diseases (1.6%; p = 0.02) by ELISA. This difference in reactivity was restricted to the CSF as serum reactivity against RBPJ did not differ between patients and controls. The presence of CSF autoantibodies against RBPJ was further confirmed by immunocytochemistry. CONCLUSIONS: These data indicate that RBPJ, a ubiquitous protein of the Notch signaling pathway that plays an important role in Epstein-Barr virus infection, is a novel MS autoantigen candidate that is recognized by CSF-derived immunoglobulin G in a subset of patients with MS.
OBJECTIVE: To profile the reactivity of CSF-derived immunoglobulin from patients with multiple sclerosis (MS) against a large panel of antigens, to identify disease-specific reactivities. METHODS:CSF from subjects with MS with elevated immunoglobulin G and CSF from control subjects presenting with other inflammatory neurologic disease were screened against a protein array consisting of 9,393 proteins. Reactivity to a candidate protein identified using these arrays was confirmed with ELISA and immunocytochemistry. RESULTS: Autoantibodies against one protein on the array, recombination signal binding protein for immunoglobulin kappa J region (RBPJ), discriminated between patients with MS and controls (p = 0.0052). Using a large validation cohort, we found a higher prevalence of autoantibodies against RBPJ in the CSF of patients with MS (12.5%) compared with the CSF of patients with other neurologic diseases (1.6%; p = 0.02) by ELISA. This difference in reactivity was restricted to the CSF as serum reactivity against RBPJ did not differ between patients and controls. The presence of CSF autoantibodies against RBPJ was further confirmed by immunocytochemistry. CONCLUSIONS: These data indicate that RBPJ, a ubiquitous protein of the Notch signaling pathway that plays an important role in Epstein-Barr virus infection, is a novel MS autoantigen candidate that is recognized by CSF-derived immunoglobulin G in a subset of patients with MS.
Authors: Matthew T Maurano; Richard Humbert; Eric Rynes; Robert E Thurman; Eric Haugen; Hao Wang; Alex P Reynolds; Richard Sandstrom; Hongzhu Qu; Jennifer Brody; Anthony Shafer; Fidencio Neri; Kristen Lee; Tanya Kutyavin; Sandra Stehling-Sun; Audra K Johnson; Theresa K Canfield; Erika Giste; Morgan Diegel; Daniel Bates; R Scott Hansen; Shane Neph; Peter J Sabo; Shelly Heimfeld; Antony Raubitschek; Steven Ziegler; Chris Cotsapas; Nona Sotoodehnia; Ian Glass; Shamil R Sunyaev; Rajinder Kaul; John A Stamatoyannopoulos Journal: Science Date: 2012-09-05 Impact factor: 47.728
Authors: Birgit Obermeier; Laura Lovato; Reinhard Mentele; Wolfgang Brück; Ignasi Forne; Axel Imhof; Friedrich Lottspeich; Katherine W Turk; Simon N Willis; Hartmut Wekerle; Reinhard Hohlfeld; David A Hafler; Kevin C O'Connor; Klaus Dornmair Journal: J Neuroimmunol Date: 2011-02-24 Impact factor: 3.478
Authors: Alexander G Gabibov; Alexey A Belogurov; Yakov A Lomakin; Maria Yu Zakharova; Marat E Avakyan; Viktorya V Dubrovskaya; Ivan V Smirnov; Alexis S Ivanov; Andrey A Molnar; Vladimir E Gurtsevitch; Sergey V Diduk; Ksenia V Smirnova; Bérangère Avalle; Svetlana N Sharanova; Alfonso Tramontano; Alain Friboulet; Alexey N Boyko; Natalia A Ponomarenko; Nina V Tikunova Journal: FASEB J Date: 2011-08-22 Impact factor: 5.191
Authors: Kathryn M Brennan; Francesc Galban-Horcajo; Simon Rinaldi; Colin P O'Leary; Carl S Goodyear; Gabriela Kalna; Ariel Arthur; Christina Elliot; Sue Barnett; Christopher Linington; Jeffrey L Bennett; Gregory P Owens; Hugh J Willison Journal: J Neuroimmunol Date: 2011-08-26 Impact factor: 3.478
Authors: Rajneesh Srivastava; Muhammad Aslam; Sudhakar Reddy Kalluri; Lucas Schirmer; Dorothea Buck; Björn Tackenberg; Veit Rothhammer; Andrew Chan; Ralf Gold; Achim Berthele; Jeffrey L Bennett; Thomas Korn; Bernhard Hemmer Journal: N Engl J Med Date: 2012-07-12 Impact factor: 91.245
Authors: Burcu Ayoglu; Nicholas Mitsios; Ingrid Kockum; Mohsen Khademi; Arash Zandian; Ronald Sjöberg; Björn Forsström; Johan Bredenberg; Izaura Lima Bomfim; Erik Holmgren; Hans Grönlund; André Ortlieb Guerreiro-Cacais; Nada Abdelmagid; Mathias Uhlén; Tim Waterboer; Lars Alfredsson; Jan Mulder; Jochen M Schwenk; Tomas Olsson; Peter Nilsson Journal: Proc Natl Acad Sci U S A Date: 2016-02-09 Impact factor: 11.205
Authors: Joel N H Stern; Gur Yaari; Jason A Vander Heiden; George Church; William F Donahue; Rogier Q Hintzen; Anita J Huttner; Jon D Laman; Rashed M Nagra; Alyssa Nylander; David Pitt; Sriram Ramanan; Bilal A Siddiqui; Francois Vigneault; Steven H Kleinstein; David A Hafler; Kevin C O'Connor Journal: Sci Transl Med Date: 2014-08-06 Impact factor: 17.956
Authors: Michael Hecker; Brit Fitzner; Matthias Wendt; Peter Lorenz; Kristin Flechtner; Felix Steinbeck; Ina Schröder; Hans-Jürgen Thiesen; Uwe Klaus Zettl Journal: Mol Cell Proteomics Date: 2016-02-01 Impact factor: 5.911
Authors: Vito A G Ricigliano; Adam E Handel; Geir K Sandve; Viviana Annibali; Giovanni Ristori; Rosella Mechelli; M Zameel Cader; Marco Salvetti Journal: PLoS One Date: 2015-04-08 Impact factor: 3.240
Authors: Simon N Willis; Panos Stathopoulos; Anne Chastre; Shannon D Compton; David A Hafler; Kevin C O'Connor Journal: Front Immunol Date: 2015-11-25 Impact factor: 7.561